Ohtuvayre Access Update: What Patients Need to Know in 2026

If you or a family member takes Ohtuvayre (ensifentrine) for COPD — or has recently been prescribed it — you may be wondering about its availability in 2026. Reports of difficulty filling the prescription have been circulating, and it's natural to ask whether there's a shortage. Here's everything you need to know.

Is Ohtuvayre in an FDA Shortage in 2026?

No. As of 2026, the FDA has not listed Ohtuvayre (ensifentrine) in its official Drug Shortage Database. Verona Pharma continues to manufacture and supply the medication through its specialty pharmacy network.

However, "no shortage" doesn't mean "easy to get." The real barriers to Ohtuvayre access in 2026 are structural: specialty pharmacy exclusivity, prior authorization requirements, high cost, and evolving insurance formulary decisions. For many patients, these barriers feel indistinguishable from a shortage.

Why Is Ohtuvayre So Hard to Get If There's No Shortage?

Ohtuvayre received FDA approval on June 26, 2024 — making it one of the newest COPD medications on the market. Being a first-in-class specialty drug, several factors combine to make it difficult to access:

Specialty pharmacy only: Ohtuvayre cannot be dispensed at standard retail pharmacies. It's only available through Verona Pharma's authorized specialty pharmacy network.

Prior authorization delays: Most commercial and Medicare plans require PA before covering Ohtuvayre. The process typically takes 2 to 4 weeks.

High list price: At approximately $2,950 per month, Ohtuvayre's cost without insurance assistance is out of reach for most patients.

Formulary uncertainty: Some insurance plans have placed Ohtuvayre on high specialty tiers or have not yet added it to formulary, leading to coverage denials.

ICER affordability concern: The Institute for Clinical and Economic Review (ICER) issued an access and affordability alert for Ohtuvayre, noting the price is above typical cost-effectiveness thresholds. This has made some payers hesitant.

How Has Ohtuvayre Availability Changed Since Its Launch?

When Ohtuvayre launched in Q3 2024, it was available through a limited network of exclusive accredited specialty pharmacies. Verona Pharma has since expanded access through the Verona Pathway Plus program, which coordinates insurance approvals, specialty pharmacy connections, and financial assistance for eligible patients.

More insurance plans have also begun establishing coverage policies for Ohtuvayre as of 2025–2026, though prior authorization remains required by virtually all plans. The 2025 GOLD COPD guidelines acknowledged Ohtuvayre as a potential add-on therapy for patients with persistent dyspnea despite two long-acting bronchodilators — which may help strengthen PA appeals.

What to Do If You Can't Get Your Ohtuvayre Filled

If you're experiencing difficulty accessing Ohtuvayre in 2026, here are the most effective steps to take:

Call Verona Pathway Plus (1-833-372-8492). This is the fastest route to resolving most access issues. Their Care Coordinators can help with specialty pharmacy enrollment, PA coordination, and financial assistance.

Ask your doctor to expedite the PA. Have your doctor's office submit the PA request immediately, including all required spirometry results and clinical notes. Citing the ENHANCE trial data and the 2025 GOLD guidelines can strengthen the request.

Appeal a denial if needed. If your insurance denies coverage, file an appeal with a letter of medical necessity. Many denials are overturned on appeal.

Check your financial assistance eligibility. Commercially insured patients may pay as little as $0 per month through the Verona Pathway Plus copay program. Uninsured and underinsured patients may qualify for additional assistance.

Use medfinder to locate your pharmacy. Once your PA is approved, medfinder can help you identify which specialty pharmacy in the authorized network currently has Ohtuvayre available. medfinder calls pharmacies on your behalf and texts you the results.

What If My Insurance Keeps Denying Ohtuvayre?

If your insurer has denied Ohtuvayre coverage and appeals have been unsuccessful, talk to your doctor about alternative COPD maintenance medications. Options include tiotropium (Spiriva Respimat), Trelegy Ellipta, Breztri Aerosphere, or roflumilast (Daliresp). Each has different coverage status, cost, and effectiveness profiles.

See our full guide to Ohtuvayre alternatives for COPD for a side-by-side comparison.

The Bottom Line for 2026

There is no FDA shortage of Ohtuvayre in 2026. But access barriers — specialty pharmacy distribution, prior authorization, and cost — remain real obstacles for COPD patients. The situation is improving as more insurers finalize coverage policies and the Verona Pathway Plus program matures. With the right steps and persistence, most patients with appropriate medical need can access Ohtuvayre in 2026. Start with the Pathway Plus enrollment and work with your doctor's office closely on the PA process.